Development of pressure-sensitive dosage forms with a core liquefying at body temperature

European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V
Lisa WildeWerner Weitschies

Abstract

Pressure-sensitive dosage forms have been developed that are intended for pulsatile delivery of drugs to the proximal small intestine. The novel dosage forms are composed of insoluble shell and either a hard fat W32 or polyethylene glycol (PEG) 1000 core that are both liquidizing at body temperature. The release is triggered by predominant pressure waves such as contractions of the pylorus causing rupture of the shell and an immediate emptying of the liquefied filling containing the active ingredient. In consequence immediately after the trigger has been effective the total amount of the drug is intended to be available for absorption in the upper small intestine. Both core types were coated with a cellulose acetate film that creates a pressure-sensitive shell in which mechanical resistance is depending on the coating thickness. Results of the texture analysis confirmed a correlation between the polymer load of the coating and the mechanical resistance. The dissolution test performed under conditions of physiological meaningful mechanical stress showed that the drug release is triggered by pressure waves of ⩾300 mbar which are representing the maximal pressure occurring during the gastric emptying.

References

Apr 1, 1989·Digestive Diseases and Sciences·A OuyangJ C Reynolds
Nov 5, 1998·Journal of Controlled Release : Official Journal of the Controlled Release Society·Z HuK Takada
Nov 7, 2000·International Journal of Pharmaceutics·M KambaK Nishimura
Sep 29, 2001·International Journal of Pharmaceutics·M KambaK Nishimura
Mar 7, 2002·International Journal of Pharmaceutics·Libo YangJoseph A Fix
Apr 17, 2002·International Journal of Pharmaceutics·Masaharu KambaKenji Nishimura
Jul 28, 2004·Alimentary Pharmacology & Therapeutics·C BottJ Stein
Feb 15, 2005·Drug Discovery Today·Stanley S Davis
Nov 5, 2005·Alimentary Pharmacology & Therapeutics·C SchillerW Weitschies
Jan 16, 2008·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·D CassillyH P Parkman
Jun 28, 2008·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Grzegorz GarbaczWerner Weitschies
May 2, 2009·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Youness KarroutJuergen Siepmann
Nov 26, 2009·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Fang LiuAbdul W Basit
Oct 28, 2010·Expert Opinion on Drug Delivery·Grzegorz GarbaczWerner Weitschies
Jun 13, 2012·The Journal of Pharmacy and Pharmacology·Grzegorz Garbacz, Sandra Klein

❮ Previous
Next ❯

Citations

Apr 3, 2016·Advanced Drug Delivery Reviews·Mirko KoziolekWerner Weitschies
Aug 10, 2016·Medicinal Research Reviews·Nir Debotton, Arik Dahan
Oct 28, 2016·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Jens Van Den AbeelePatrick Augustijns

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.